Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3918792 | EAU-EBU Update Series | 2006 | 10 Pages |
Abstract
Over the last 10 years definite advances have been made in the treatment of advanced hormone-refractory prostate cancer (HRPC). Present chemotherapeutics for HRPC can provide palliation, and as demonstrated by two large recent randomized trials using docetaxel-based therapy, a modest improvement in overall survival. A number of novel therapeutics are becoming standard of care or are under development including novel chemotherapeutics, bisphosphonates, immunotherapeutics, nucleotide-based targeted therapy, endothelin receptor antagonists, and angiogenesis inhibitors. Development of these novel therapeutics will be essential to provide clinicians multiple avenues through which prostate cancer can be effectively treated.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Richard D. Sowery, Alan I. So, Martin E. Gleave,